Celcuity Inc Announces Worldwide Licensing Agreement with Pfizer - Corporate Call Transcript
Greetings. Welcome to the Celcuity-Pfizer License Agreement Conference. (Operator Instructions)
Please note, this conference is being recorded. I will now turn the conference over to your host, Brian Sullivan, Chief Executive Officer and Co-Founder of Celcuity. Thank you. You may begin.
Good afternoon, everyone. Thank you for attending this call. We have quite a news to report. We issued 2 press releases today, one announcing a global license agreement with Pfizer for a small molecule inhibitor, gedatolisib; the second press release we issued provides additional details about results from a Phase Ib trial, details about our team and updates on debt financing that we closed today as well.
So turning to Page 2 of the presentation, if you're on the webcast. I'd first start off with the background about the rationale and how we arrived at the decision and ultimately, to license gedatolisib. I'd like to provide an overview of gedatolisib's mechanism and its advantages relative to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
